Upstream Bio Inc (UPB)

$8.06 +0.40 (5.22%)
Market Cap 413.94M
Revenue (ttm) 2.37M
Net Income (ttm) -62.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,650.21%
Debt to Equity Ratio 0.00
Volume 1,194,600
Avg Vol 1,329,322
Day's Range N/A - N/A
Shares Out 54.04M
Stochastic %K 76%
Beta 2.96
Analysts Strong Sell
Price Target $48.50

Company Profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Industry: Biotechnology
Sector: Healthcare
Phone: 781 208 2466
Address:
890 Winter Street, Suite 200, Waltham, United States
Off_The_Top_Rope
Off_The_Top_Rope Mar. 9 at 9:27 PM
$UPB Big gap to close at $26!
0 · Reply
fantastex
fantastex Mar. 5 at 2:00 PM
$UPB jeez this stock cant hold some gains
0 · Reply
RocketCityRetai1
RocketCityRetai1 Mar. 4 at 6:06 PM
$UPB finally we’re making something shake
0 · Reply
fantastex
fantastex Mar. 4 at 1:42 PM
$UPB sleeper giant. Sad I got in at 7.75 when there was some space for the downside
0 · Reply
Eliteh
Eliteh Mar. 2 at 7:33 PM
$UPB Even a 100% increase puts the market cap at <$1B....
1 · Reply
Eliteh
Eliteh Mar. 2 at 7:32 PM
$UPB now that every single person holding this has been liquidated or margin called, I personally expect it revert directions. Ph3 ready drug expected to do blockbuster sales, ya this is games being played.
0 · Reply
nikserr
nikserr Mar. 2 at 4:02 PM
$UPB This will trade $10+ in no time and $15+ in a little bit of time. Collect your shares before they are gone.
0 · Reply
AlertsAndNews
AlertsAndNews Mar. 1 at 11:29 PM
$UPB Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting "Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use. Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001)"
0 · Reply
fantastex
fantastex Mar. 1 at 7:54 PM
$UPB As previously reported in the top-line results, verekitug reduced the need for surgery or systemic corticosteroids by 76@% This opens 10+ on Monday
1 · Reply
StockNews_Live
StockNews_Live Mar. 1 at 2:45 PM
$UPB Upstream Bio presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial showed a placebo-a…
0 · Reply
Latest News on UPB
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Mar 1, 2026, 9:45 AM EST - 8 days ago

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Feb 26, 2026, 7:00 AM EST - 11 days ago

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Upstream Bio to Participate in Upcoming March Investor Conferences

Feb 25, 2026, 7:00 AM EST - 12 days ago

Upstream Bio to Participate in Upcoming March Investor Conferences

Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Feb 13, 2026, 10:45 AM EST - 24 days ago

Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Feb 11, 2026, 9:02 AM EST - 26 days ago

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Feb 11, 2026, 6:00 AM EST - 26 days ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Feb 10, 2026, 6:00 PM EST - 27 days ago

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 2 months ago

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study

Dec 5, 2025, 4:48 PM EST - 3 months ago

Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study

Upstream Bio to Participate in Upcoming December Investor Conferences

Nov 25, 2025, 7:00 AM EST - 3 months ago

Upstream Bio to Participate in Upcoming December Investor Conferences

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Nov 5, 2025, 7:00 AM EST - 4 months ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio to Participate in Upcoming November Investor Conferences

Oct 31, 2025, 7:00 AM EDT - 4 months ago

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Sep 30, 2025, 4:15 AM EDT - 5 months ago

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Sep 9, 2025, 7:00 AM EDT - 6 months ago

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio, Inc. - Special Call

Sep 7, 2025, 10:25 PM EDT - 6 months ago

Upstream Bio, Inc. - Special Call

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 2, 2025, 6:00 AM EDT - 6 months ago

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Sep 1, 2025, 5:00 PM EDT - 6 months ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Jul 8, 2025, 7:00 AM EDT - 8 months ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Jun 15, 2025, 7:45 AM EDT - 9 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Jun 5, 2025, 7:00 AM EDT - 9 months ago

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 7:00 AM EDT - 9 months ago

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Upstream Bio Appoints Stacy Price as Chief Technology Officer

May 20, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

May 6, 2025, 7:00 AM EDT - 10 months ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

Apr 17, 2025, 5:51 PM EDT - 11 months ago

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

3 Dividend Giants To Buy As Tariffs Hit Stocks

Mar 28, 2025, 3:56 PM EDT - 1 year ago

3 Dividend Giants To Buy As Tariffs Hit Stocks

PEP PG

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio to Present at Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 1 year ago

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Dec 16, 2024, 1:03 PM EST - 1 year ago

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio Announces Addition to Russell 2000® Index

Dec 16, 2024, 8:00 AM EST - 1 year ago

Upstream Bio Announces Addition to Russell 2000® Index

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Nov 5, 2024, 3:09 PM EST - 1 year ago

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 15, 2024, 4:15 PM EDT - 1 year ago

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Oct 11, 2024, 12:49 PM EDT - 1 year ago

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Upstream Bio raises $255 mln in US IPO

Oct 10, 2024, 7:42 PM EDT - 1 year ago

Upstream Bio raises $255 mln in US IPO

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Oct 10, 2024, 7:35 PM EDT - 1 year ago

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Off_The_Top_Rope
Off_The_Top_Rope Mar. 9 at 9:27 PM
$UPB Big gap to close at $26!
0 · Reply
fantastex
fantastex Mar. 5 at 2:00 PM
$UPB jeez this stock cant hold some gains
0 · Reply
RocketCityRetai1
RocketCityRetai1 Mar. 4 at 6:06 PM
$UPB finally we’re making something shake
0 · Reply
fantastex
fantastex Mar. 4 at 1:42 PM
$UPB sleeper giant. Sad I got in at 7.75 when there was some space for the downside
0 · Reply
Eliteh
Eliteh Mar. 2 at 7:33 PM
$UPB Even a 100% increase puts the market cap at <$1B....
1 · Reply
Eliteh
Eliteh Mar. 2 at 7:32 PM
$UPB now that every single person holding this has been liquidated or margin called, I personally expect it revert directions. Ph3 ready drug expected to do blockbuster sales, ya this is games being played.
0 · Reply
nikserr
nikserr Mar. 2 at 4:02 PM
$UPB This will trade $10+ in no time and $15+ in a little bit of time. Collect your shares before they are gone.
0 · Reply
AlertsAndNews
AlertsAndNews Mar. 1 at 11:29 PM
$UPB Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting "Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use. Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001)"
0 · Reply
fantastex
fantastex Mar. 1 at 7:54 PM
$UPB As previously reported in the top-line results, verekitug reduced the need for surgery or systemic corticosteroids by 76@% This opens 10+ on Monday
1 · Reply
StockNews_Live
StockNews_Live Mar. 1 at 2:45 PM
$UPB Upstream Bio presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial showed a placebo-a…
0 · Reply
fantastex
fantastex Feb. 28 at 1:10 PM
$UPB cubie what you think about this stock? Data on Sunday @cubie
1 · Reply
Chasse_patate
Chasse_patate Feb. 27 at 4:19 PM
$UPB Interest very low, wait until that changes.
1 · Reply
fantastex
fantastex Feb. 27 at 9:17 AM
$UPB new analysis on Sunday. 10+
0 · Reply
acarsoy
acarsoy Feb. 26 at 7:08 PM
$UPB I can wait
0 · Reply
lordBrian
lordBrian Feb. 26 at 4:28 PM
$UPB who else for a dead bag of this bought it way to high whoops
0 · Reply
bababooey143
bababooey143 Feb. 26 at 3:26 PM
$UPB
0 · Reply
Cheaslea76
Cheaslea76 Feb. 26 at 9:03 AM
$UPB
0 · Reply
fantastex
fantastex Feb. 25 at 8:54 PM
$UPB when the stream starts here..... 10+ next month. Successfull drugs and 300m in cash and market cap 400m lol 2x here.
0 · Reply
theBigDollarski
theBigDollarski Feb. 24 at 2:18 PM
$UPB $TARA when good news becomes accumulation time.
1 · Reply
Cheaslea76
Cheaslea76 Feb. 24 at 1:07 PM
$UPB
1 · Reply
nikserr
nikserr Feb. 23 at 7:18 PM
$UPB there is nothing weird going on. this is how they collect more shares. the pump will come sooner or later. collect as much you could and wait for the pump.
0 · Reply
SouthernSky1
SouthernSky1 Feb. 23 at 6:23 PM
$UPB I agree something weird is going on. No news, insider buys or sells, or even comments from mgmt in about ten days regarding the sudden drop. Volume appears to have come back to average.
0 · Reply